Jacobs Journal of Diabetes and Endocrinology

The Influence of Hashimoto’s Thyroiditis Lymphocytic Infiltration in BRAFV600E Mutation Positive Papillary Thyroid Carcinoma

Published on: 2018-10-25

Abstract

Background: Papillary thyroid carcinoma (PTC) and Hashimoto’s thyroiditis (HT) are frequently present together. BRAFV600E mutation may be associated with a more advanced PTC at diagnosis. We evaluated the influence of HT in BRAFV600E mutation positive PTC with clinicopathologic features. Methods: The study was performed on 66 PTC patients after surgical management from January 2012 to December 2012. BRAFV600E mutation analysis was performed by polymerase chain reaction (PCR)- based amplification of DNA extracted from paraffin-embedded tumor specimens.

Results: 24cases (36.4%) among 66 PTC patients had concomitant HT. Statistical analysis showed no significant difference between PTC with concurrent HT (PTCHT+) and without concurrent HT (PTCHT-) in several clincopathologic features (age, sex, size, multiplicity, lymph node metastasis and extrathyroidal extension). But some correlation was noted in female gender in PTCHT+(P-value; 0.082). BRAFV600E mutation was observed in 50 (75.8%) of 66 patients with PTC. 32 cases among 42 cases of PTCHT- and 18 cases among 24 cases of PTCHT+ showed BRAFV600E mutation. There was no significant difference between PTCHT+ and PTCHT- in BRAFV600E mutation rate. But in BRAF V600E mutaton positive PTC, PTCHT+ showed significant less frequent lymph node metastasis than PTCHT- (P-value; 0.035).

Conclusion: Some correlation was noted in female gender in PTCHT+(P-value; 0.082) although statistically not significant. There was no significant difference between PTCHT+ and PTCHT- in BRAFV600E mutation rate. But in BRAF V600E positive PTC, PTCHT+ showed significant less frequent lymph node metastasis than PTCHT- (P-value; 0.035)

Keywords

Hashimoto thyroiditis; Papillary thyroid carcinoma; BRAF mutation.